{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:09:24Z","timestamp":1774458564943,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2015\/10109-5"],"award-info":[{"award-number":["2015\/10109-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2015\/18125-0"],"award-info":[{"award-number":["2015\/18125-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"DOI":"10.1007\/s40520-023-02452-5","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T02:02:46Z","timestamp":1685671366000},"page":"1741-1752","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8311-0859","authenticated-orcid":false,"given":"Fabricio Ferreira","family":"de Oliveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1035-027X","authenticated-orcid":false,"given":"Marjorie C\u00e2mara","family":"Miraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-3004","authenticated-orcid":false,"given":"Eduardo Ferreira","family":"de Castro-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4392-0953","authenticated-orcid":false,"given":"Sandro Soares","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0479-2450","authenticated-orcid":false,"given":"Sandro Luiz de Andrade","family":"Matas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7902-7502","authenticated-orcid":false,"given":"Paulo Henrique Ferreira","family":"Bertolucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-360X","authenticated-orcid":false,"given":"Maria da Gra\u00e7a","family":"Naffah-Mazzacoratti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"2452_CR1","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jalz.2018.03.004","volume":"14","author":"N Silverberg","year":"2018","unstructured":"Silverberg N, Elliott C, Ryan L et al (2018) NIA commentary on the NIA-AA research framework: towards a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14:576\u2013578","journal-title":"Alzheimers Dement"},{"key":"2452_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000500567","volume":"47","author":"GP Paraskevas","year":"2019","unstructured":"Paraskevas GP, Bougea A, Constantinides VC et al (2019) In vivo prevalence of Alzheimer biomarkers in dementia with Lewy bodies. Dement Geriatr Cogn Disord 47:289\u2013296","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2452_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 89:88\u2013100","journal-title":"Neurology"},{"key":"2452_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.105832","volume":"194","author":"FF De Oliveira","year":"2020","unstructured":"De Oliveira FF, Machado FC, Sampaio G et al (2020) Neuropsychiatric feature profiles of patients with Lewy body dementia. Clin Neurol Neurosurg 194:105832","journal-title":"Clin Neurol Neurosurg"},{"key":"2452_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/S0004-282X1994000100001","volume":"52","author":"PHF Bertolucci","year":"1994","unstructured":"Bertolucci PHF, Brucki SMD, Campacci SR et al (1994) The mini-mental state examination in an outpatient population: influence of literacy. Arq Neuropsiquiatr 52:1\u20137","journal-title":"Arq Neuropsiquiatr"},{"key":"2452_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1590\/0004-282X20140002","volume":"72","author":"JR Wajman","year":"2014","unstructured":"Wajman JR, Oliveira FF, Schultz RR et al (2014) Educational bias in the assessment of severe dementia: Brazilian cutoffs for severe mini-mental state examination. Arq Neuropsiquiatr 72:273\u2013277","journal-title":"Arq Neuropsiquiatr"},{"key":"2452_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clineuro.2015.05.010","volume":"135","author":"FF De Oliveira","year":"2015","unstructured":"De Oliveira FF, Wajman JR, Bertolucci PHF et al (2015) Correlations among cognitive and behavioural assessments in patients with dementia due to Alzheimer\u2019s disease. Clin Neurol Neurosurg 135:27\u201333","journal-title":"Clin Neurol Neurosurg"},{"key":"2452_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2190\/UURL-2RYU-WRYD-EY3K","volume":"6","author":"S Katz","year":"1976","unstructured":"Katz S, Akpom CA (1976) A measure of primary socio-biological functions. Int J Health Serv 6:493\u2013508","journal-title":"Int J Health Serv"},{"key":"2452_CR9","first-page":"789","volume":"24","author":"MP Lawton","year":"1988","unstructured":"Lawton MP (1988) Instrumental activities of daily living (IADL) scale: self-reported version. Psychopharmacol Bull 24:789\u2013791","journal-title":"Psychopharmacol Bull"},{"key":"2452_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1590\/S0102-311X2004000200004","volume":"20","author":"A Taub","year":"2004","unstructured":"Taub A, Andreoli SB, Bertolucci PHF (2004) Dementia caregiver burden: reliability of the Brazilian version of the Zarit caregiver burden interview. Cad Saude Publica 20:372\u2013376","journal-title":"Cad Saude Publica"},{"key":"2452_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/alz.12365","volume":"18","author":"M Boccardi","year":"2022","unstructured":"Boccardi M, Monsch A, Ferrari C et al (2022) Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimers Dement 18:29\u201342","journal-title":"Alzheimers Dement"},{"key":"2452_CR12","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1007\/s40520-020-01774-y","volume":"33","author":"P Soysal","year":"2021","unstructured":"Soysal P, Tan SG (2021) The prevalence and co-incidence of geriatric syndromes in older patients with early-stage Alzheimer\u2019s disease and dementia with Lewy bodies. Aging Clin Exp Res 33:2599\u20132603","journal-title":"Aging Clin Exp Res"},{"key":"2452_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cca.2019.04.078","volume":"495","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Paciotti S, Farotti L et al (2019) Parkinson\u2019s and Lewy body dementia CSF biomarkers. Clin Chim Acta 495:318\u2013325","journal-title":"Clin Chim Acta"},{"key":"2452_CR14","doi-asserted-by":"publisher","first-page":"5864","DOI":"10.1038\/s41380-020-00950-w","volume":"26","author":"A Sala","year":"2021","unstructured":"Sala A, Nordberg A, Rodriguez-Vieitez E (2021) Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-\u03b2 positivity. Mol Psychiatry 26:5864\u20135874","journal-title":"Mol Psychiatry"},{"key":"2452_CR15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3233\/JAD-210272","volume":"81","author":"FF De Oliveira","year":"2021","unstructured":"De Oliveira FF, Miraldo MC, Castro-Neto EF et al (2021) Associations of neuropsychiatric features with cerebrospinal fluid biomarkers of amyloidogenesis and neurodegeneration in dementia with Lewy bodies compared with Alzheimer\u2019s disease and cognitively healthy people. J Alzheimers Dis 81:1295\u20131309","journal-title":"J Alzheimers Dis"},{"key":"2452_CR16","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/mds.111","volume":"33","author":"I van Steenoven","year":"2018","unstructured":"van Steenoven I, Majbour NK, Vaikath NN et al (2018) \u03b1-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with Lewy bodies. Mov Disord 33:1724\u20131733","journal-title":"Mov Disord"},{"key":"2452_CR17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/brain\/awaa395","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Ossenkoppele R et al (2021) Untangling the association of amyloid-\u03b2 and tau with synaptic and axonal loss in Alzheimer\u2019s disease. Brain 144:310\u2013324","journal-title":"Brain"},{"key":"2452_CR18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00401-013-1148-z","volume":"126","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Korff A, Shaw LM et al (2013) CSF \u03b1-synuclein improves diagnostic and prognostic performance of CSF tau and A\u03b2 in Alzheimer\u2019s disease. Acta Neuropathol 126:683\u2013697","journal-title":"Acta Neuropathol"},{"key":"2452_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.neurobiolaging.2021.06.004","volume":"106","author":"JH Jung","year":"2021","unstructured":"Jung JH, Jeon S, Baik K et al (2021) Apolipoprotein E4, amyloid, and cognition in Alzheimer\u2019s and Lewy body disease. Neurobiol Aging 106:45\u201354","journal-title":"Neurobiol Aging"},{"key":"2452_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.25530","volume":"86","author":"G Leonenko","year":"2019","unstructured":"Leonenko G, Shoai M, Bellou E et al (2019) Genetic risk for Alzheimer disease is distinct from genetic risk for amyloid deposition. Ann Neurol 86:427\u2013435","journal-title":"Ann Neurol"},{"key":"2452_CR21","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/jamapsychiatry.2014.1060","volume":"71","author":"R Lautner","year":"2014","unstructured":"Lautner R, Palmqvist S, Mattson N et al (2014) Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiat 71:1183\u20131191","journal-title":"JAMA Psychiat"},{"key":"2452_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0b013e3181b23564","volume":"73","author":"A Okello","year":"2009","unstructured":"Okello A, Koivunen J, Edison P et al (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73:754\u2013760","journal-title":"Neurology"},{"key":"2452_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the national institute on aging and the Alzheimer\u2019s association workgroup. Alzheimers Dement 7:263\u2013269","journal-title":"Alzheimers Dement"},{"key":"2452_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/WAD.0b013e31811ff2b4","volume":"21","author":"MLF Chaves","year":"2007","unstructured":"Chaves MLF, Camozzato AL, Godinho C et al (2007) Validity of the clinical dementia rating scale for the detection and staging of dementia in Brazilian patients. Alzheimer Dis Assoc Disord 21:210\u2013217","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2452_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1161\/01.STR.14.3.399","volume":"14","author":"C Loeb","year":"1983","unstructured":"Loeb C, Gandolfo C (1983) Diagnostic evaluation of degenerative and vascular dementia. Stroke 14:399\u2013401","journal-title":"Stroke"},{"key":"2452_CR26","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1056\/NEJMcp0910237","volume":"364","author":"RC Petersen","year":"2011","unstructured":"Petersen RC (2011) Mild cognitive impairment. N Engl J Med 364:2227\u20132234","journal-title":"N Engl J Med"},{"key":"2452_CR27","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Petzold A, Bennett JL et al (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73:1914\u20131922","journal-title":"Neurology"},{"key":"2452_CR28","doi-asserted-by":"publisher","DOI":"10.17632\/39xyyjdsf3.1","author":"F Oliveira","year":"2023","unstructured":"Oliveira F (2023) Data for: differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer\u2019s disease. Mendeley Data V1. https:\/\/doi.org\/10.17632\/39xyyjdsf3.1","journal-title":"Mendeley Data V1"},{"key":"2452_CR29","first-page":"42","volume":"7","author":"AE Budson","year":"2007","unstructured":"Budson AE, Price BH (2007) Memory dysfunction in neurological practice. Pract Neurol 7:42\u201347","journal-title":"Pract Neurol"},{"key":"2452_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13195-018-0361-3","volume":"10","author":"RW Paterson","year":"2018","unstructured":"Paterson RW, Slattery CF, Poole T et al (2018) Cerebrospinal fluid in the differential diagnosis of Alzheimer\u2019s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimers Res Ther 10:32","journal-title":"Alzheimers Res Ther"},{"key":"2452_CR31","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jalz.2013.12.023","volume":"10","author":"FH Duits","year":"2014","unstructured":"Duits FH, Teunissen CE, Bouwman FH et al (2014) The cerebrospinal fluid \u201cAlzheimer profile\u201d: easily said, but what does it mean? Alzheimers Dement 10:713\u2013723","journal-title":"Alzheimers Dement"},{"key":"2452_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JAD-130995","volume":"38","author":"L Kaerst","year":"2014","unstructured":"Kaerst L, Kuhlmann A, Wedekind D et al (2014) Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson\u2019s disease, and Alzheimer\u2019s disease. J Alzheimers Dis 38:63\u201373","journal-title":"J Alzheimers Dis"},{"key":"2452_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13195-020-00610-9","volume":"12","author":"M van de Beek","year":"2020","unstructured":"van de Beek M, Mofrad RB, van Steenoven I et al (2020) Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies. Alzheimers Res Ther 12:44","journal-title":"Alzheimers Res Ther"},{"key":"2452_CR34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.parkreldis.2013.06.008","volume":"19","author":"X Lim","year":"2013","unstructured":"Lim X, Yeo JM, Green A et al (2013) The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies\u2014a systematic review and meta-analysis. Parkinsonism Relat Disord 19:851\u2013858","journal-title":"Parkinsonism Relat Disord"},{"key":"2452_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H, Skillb\u00e4ck T, Mattson N et al (2016) Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol 73:60\u201367","journal-title":"JAMA Neurol"},{"key":"2452_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1177\/0891988720944237","volume":"34","author":"R Ibarra","year":"2021","unstructured":"Ibarra R, Radanovic M, Pais MV et al (2021) AD-related CSF biomarkers across distinct levels of cognitive impairment: correlations with global cognitive state. J Geriatr Psychiatry Neurol 34:659\u2013667","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"2452_CR37","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1212\/01.WNL.0000158423.05224.7F","volume":"64","author":"JM Burns","year":"2005","unstructured":"Burns JM, Galvin JE, Roe CM et al (2005) The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs. Neurology 64:1397\u20131403","journal-title":"Neurology"},{"key":"2452_CR38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13195-021-00909-1","volume":"13","author":"EH Seo","year":"2021","unstructured":"Seo EH, Lim HJ, Yoon HJ et al (2021) Visuospatial memory impairment as a potential neurocognitive marker to predict tau pathology in Alzheimer\u2019s continuum. Alzheimers Res Ther 13:167","journal-title":"Alzheimers Res Ther"},{"key":"2452_CR39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","volume":"10","author":"ME Murray","year":"2011","unstructured":"Murray ME, Graff-Radford NR, Ross OA et al (2011) Neuropathologically defined subtypes of Alzheimer\u2019s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 10:785\u2013796","journal-title":"Lancet Neurol"},{"key":"2452_CR40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3233\/JAD-121810","volume":"34","author":"JK Dieks","year":"2013","unstructured":"Dieks JK, Gawinecka J, Asif AR et al (2013) Low-abundant cerebrospinal fluid proteome alterations in dementia with Lewy bodies. J Alzheimers Dis 34:387\u2013397","journal-title":"J Alzheimers Dis"},{"key":"2452_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/NRL.0000000000000045","volume":"20","author":"FF Oliveira","year":"2015","unstructured":"Oliveira FF, Machado FC, Sampaio G et al (2015) Contrasts between patients with Lewy body dementia syndromes and APOE-\u03b53\/\u03b53 patients with late-onset Alzheimer disease dementia. Neurologist 20:35\u201341","journal-title":"Neurologist"},{"key":"2452_CR42","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","volume":"70","author":"MA Nalls","year":"2013","unstructured":"Nalls MA, Duran R, Lopez G et al (2013) A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 70:727\u2013735","journal-title":"JAMA Neurol"},{"key":"2452_CR43","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3233\/JAD-132246","volume":"40","author":"HM Nielsen","year":"2014","unstructured":"Nielsen HM, Hall S, Surova Y et al (2014) Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. J Alzheimers Dis 40:343\u2013350","journal-title":"J Alzheimers Dis"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-023-02452-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-023-02452-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-023-02452-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T13:08:34Z","timestamp":1690031314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-023-02452-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["2452"],"URL":"https:\/\/doi.org\/10.1007\/s40520-023-02452-5","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"assertion":[{"value":"28 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to report. All authors have read the paper and agreed to be listed as authors, having approved it and validated the accuracy of the data. Individual author contributions include, as follows: Fabricio Ferreira de Oliveira, MD, MSc, PhD, is a medical researcher of the Department of Neurology and Neurosurgery of the Federal University of S\u00e3o Paulo\u2014UNIFESP, a Member of the Committee of Experts of the European Science Foundation, of the American Academy of Neurology Global Strategies Subcommittee, of the Awards Committee of the International Parkinson and Movement Disorder Society (MDS, 2021\u20132023), and of the Executive Committee of the ISTAART Biofluid Based Biomarkers Professional Interest Area (Alzheimer\u2019s Association, 2018\u20132025); he has received research support from CAPES\u2014<i>Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior<\/i> and FAPESP\u2014The State of S\u00e3o Paulo Research Foundation, and serves as a healthcare council member for Gerson Lehrman Group, for Atheneum Partners, for Guidepoint, and for Lionbridge; he was involved in conceptualization, methodology, formal analysis, investigation, data curation, writing of the original draft, review and editing, visualization, and project administration. Marjorie C\u00e2mara Miraldo, MSc, is a researcher at the Department of Neurology and Neurosurgery of the Federal University of S\u00e3o Paulo\u2014UNIFESP; she was involved in methodology, formal analysis, investigation, data curation, review and editing of the draft. Eduardo Ferreira de Castro-Neto, MSc, PhD, is a researcher at the Department of Neurology and Neurosurgery of the Federal University of S\u00e3o Paulo\u2014UNIFESP; he was involved in methodology, formal analysis, resources, review and editing of the draft. Sandro Soares de Almeida, MSc, PhD, is a researcher at the Department of Biophysics of the Federal University of S\u00e3o Paulo\u2014UNIFESP, and has received grants from CNPq\u2014<i>Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico<\/i> and FAPESP\u2014The State of S\u00e3o Paulo Research Foundation; he was involved in conceptualization, methodology, validation, formal analysis, resources, data curation, review and editing of the draft. Sandro Luiz de Andrade Matas, MD, MSc, PhD, is a medical researcher at the Department of Neurology and Neurosurgery of the Federal University of S\u00e3o Paulo\u2014UNIFESP; he was involved in methodology, investigation, resources, review and editing of the draft. Paulo Henrique Ferreira Bertolucci, MD, MSc, PhD, is a full professor of the Department of Neurology and Neurosurgery of the Federal University of S\u00e3o Paulo\u2014UNIFESP; he has received grants from CAPES\u2014<i>Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior<\/i> and FAPESP\u2014The State of S\u00e3o Paulo Research Foundation, and serves as a consultant for Janssen, Lundbeck, Novartis, Pfizer and Support; he was involved in conceptualization, methodology, formal analysis, resources, review and editing of the draft, project administration and funding acquisition. Maria da Gra\u00e7a Naffah-Mazzacoratti, MSc, PhD, is a full professor of the Department of Neurology and Neurosurgery of the Federal University of S\u00e3o Paulo\u2014UNIFESP, and has received grants from CAPES\u2014<i>Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior<\/i>, CNPq\u2014<i>Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico<\/i>, and FAPESP\u2014The State of S\u00e3o Paulo Research Foundation; she was involved in conceptualization, methodology, formal analysis, resources, review and editing of the draft, supervision, project administration and funding acquisition.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study is part of the research project 0370\/2015 (CAAE 43868615.5.0000.5505) approved by the Ethics Committee of <i>Hospital S\u00e3o Paulo<\/i>, Federal University of S\u00e3o Paulo (UNIFESP), in June 2015, following the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study only included human participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"All invited patients and their legal representatives agreed to participate and signed the Informed Consent Form before the assessment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}